Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 2/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.35 |
| ▸ | CPT2 | P23786 | 1/20 | 0.34 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6002681 | 0.91 | MAPK14 (0.39) | CPT1ATGFBR1MAPK14USP30NTMT1 | |
| SCHEMBL4899273 | 0.90 | ACKR3 (0.40) | CPT1ATGFBR1MAPK14USP30ACKR3 | |
| SCHEMBL6003954 | 0.90 | MAPK14 (0.42) | CPT1ATGFBR1MAPK14USP30UCHL1 | |
| SCHEMBL6003655 | 0.90 | CPT1A (0.37) | CPT1ATGFBR1MAPK14USP30GRIA1 | |
| SCHEMBL6004212 | 0.88 | ACKR3 (0.38) | CPT1ATGFBR1MAPK14USP30NTMT1 | |
| SCHEMBL4790528 | 0.85 | MAPK14 (0.50) | TGFBR1MAPK14GRIA1MAPK13MAPK12 | |
| SCHEMBL6949291 | 0.78 | TGFBR1 (0.42) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6004902 | 0.78 | CPT1A (0.43) | CPT1AMAPK14PTGER1USP30MAPK11 | |
| SCHEMBL6004133 | 0.77 | MAPK14 (0.46) | TGFBR1MAPK14USP30GRIA1ACKR3 | |
| SCHEMBL6948035 | 0.77 | TGFBR1 (0.41) | TGFBR1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871770-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | Kalypsys, Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006116355-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | KALYPSYS, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | CPT1A 4225/4885TGFBR1 572/4885MAPK14 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.